![Robert J. Terifay](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert J. Terifay
Keine laufenden Positionen mehr
Karriereverlauf von Robert J. Terifay
Ehemalige bekannte Positionen von Robert J. Terifay
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 26.02.2007 | 05.01.2018 |
ArgiNOx Pharmaceuticals, Inc.
![]() ArgiNOx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ArgiNOx Pharmaceuticals, Inc. focused on the discovery and development of medicines to treat hospitalized patients. The company's initial area of research and development is directed at nitric oxide-mediated pathways. Arginox's lead compound, Tilarginine Acetate Injection, is in late-stage clinical evaluation for the treatment of cardiogenic shock. The company was incorporated on March 24, 2004 and was headquartered in Redwood City, CA. | Geschäftsführer | 01.01.2006 | 01.10.2006 |
Präsident | 01.01.2006 | 01.10.2006 | |
Synta Pharmaceuticals Corp.
![]() Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Corporate Officer/Principal | 01.03.2005 | 01.12.2005 |
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.02.2002 | 01.03.2005 |
COR Therapeutics, Inc.
![]() COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Vertrieb & Marketing | 01.01.1996 | 01.02.2002 |
Saatchi & Saatchi North America LLC
![]() Saatchi & Saatchi North America LLC Advertising/Marketing ServicesCommercial Services Saatchi & Saatchi North America, Inc. provides advertising services. It offers creative advertising services and plans marketing campaigns for advertisers and global companies. The company was founded in 1970 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.01.1993 | 01.01.1996 |
G.D. Searle & Co., Inc.
![]() G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | Corporate Officer/Principal | 01.01.1993 | 01.01.1993 |
Ausbildung von Robert J. Terifay
University of Notre Dame | Undergraduate Degree |
Kellogg School of Management | Graduate Degree |
Statistik
International
Vereinigte Staaten | 10 |
Operativ
Corporate Officer/Principal | 5 |
Undergraduate Degree | 1 |
Chief Operating Officer | 1 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
REGENERON PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
Synta Pharmaceuticals Corp.
![]() Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Health Technology |
ArgiNOx Pharmaceuticals, Inc.
![]() ArgiNOx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ArgiNOx Pharmaceuticals, Inc. focused on the discovery and development of medicines to treat hospitalized patients. The company's initial area of research and development is directed at nitric oxide-mediated pathways. Arginox's lead compound, Tilarginine Acetate Injection, is in late-stage clinical evaluation for the treatment of cardiogenic shock. The company was incorporated on March 24, 2004 and was headquartered in Redwood City, CA. | Health Technology |
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
COR Therapeutics, Inc.
![]() COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Saatchi & Saatchi North America LLC
![]() Saatchi & Saatchi North America LLC Advertising/Marketing ServicesCommercial Services Saatchi & Saatchi North America, Inc. provides advertising services. It offers creative advertising services and plans marketing campaigns for advertisers and global companies. The company was founded in 1970 and is headquartered in New York, NY. | Commercial Services |
G.D. Searle & Co., Inc.
![]() G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | Process Industries |
- Börse
- Insiders
- Robert J. Terifay
- Erfahrung